RCAG
TEVA icon

Rehmann Capital Advisory Group’s Teva Pharmaceuticals TEVA Stock Holding History

Rehmann Capital Advisory Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$2.44K Buy
355
+49
+16% +$375 ﹤0.01% 1375
2019
Q2 		$2.82K Sell
306
-9,582
-97% -$116K ﹤0.01% 1708
2019
Q1 		$155K Sell
9,888
-3,672
-27% -$64.8K 0.02% 473
2018
Q4 		$209K Buy
13,560
+3,746
+38% +$76.8K 0.03% 245
2018
Q3 		$211K Buy
9,814
+795
+9% +$18.5K 0.03% 385
2018
Q2 		$219K Buy
9,019
+5,201
+136% +$106K 0.03% 356
2018
Q1 		$65K Buy
+3,818
New +$74.5K 0.01% 670
2017
Q1 		– Sell
-6,096
Closed -$221K – 405
2016
Q4 		$221K Sell
6,096
-503
-8% -$20.1K 0.04% 346
2016
Q3 		$304K Sell
6,599
-146
-2% -$7.62K 0.06% 255
2016
Q2 		$339K Sell
6,745
-222
-3% -$11.8K 0.06% 233
2016
Q1 		$373K Buy
6,967
+86
+1% +$5.05K 0.07% 211
2015
Q4 		$452K Sell
6,881
-115
-2% -$7.11K 0.09% 166
2015
Q3 		$395K Buy
6,996
+202
+3% +$13.1K 0.09% 176
2015
Q2 		$402K Sell
6,794
-139
-2% -$8.57K 0.09% 181
2015
Q1 		$432K Sell
6,933
-88
-1% -$5.12K 0.1% 176
2014
Q4 		$404K Buy
7,021
+740
+12% +$41.2K 0.09% 187
2014
Q3 		$338K Buy
6,281
+369
+6% +$19.5K 0.08% 209
2014
Q2 		$310K Sell
5,912
-945
-14% -$48.3K 0.07% 227
2014
Q1 		$362K Buy
+6,857
New +$317K 0.1% 170

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Rehmann Capital Advisory Group's TEVA Position: Q3 2019 in Review

Rehmann Capital Advisory Group increased its Teva Pharmaceuticals (TEVA) stake by 16% in Q3 2019, buying an estimated $375 and bringing the position to 355 shares worth $2.44K. The position accounts for ﹤0.01% of the portfolio, ranked #1375.

Rehmann Capital Advisory Group first reported a position in TEVA in Q1 2014 and has held it in 19 quarters since. The position peaked at $452K in Q4 2015. 427 funds tracked by Wall St. Rank hold TEVA as of Q3 2019.

  • Rehmann Capital Advisory Group held 355 shares of Teva Pharmaceuticals worth $2.44K as of Q3 2019.
  • Rehmann Capital Advisory Group bought 49 Teva Pharmaceuticals shares in Q3 2019, an estimated $375.
  • Teva Pharmaceuticals made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1375 holding.
  • Rehmann Capital Advisory Group first reported a position in Teva Pharmaceuticals in Q1 2014 and has held it in 19 quarters since.
  • Rehmann Capital Advisory Group's Teva Pharmaceuticals position peaked at $452K in Q4 2015.
  • 427 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.